Compare NGVT & ZLAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NGVT | ZLAB |
|---|---|---|
| Founded | 1964 | 2013 |
| Country | United States | China |
| Employees | N/A | N/A |
| Industry | Major Chemicals | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.6B | 2.4B |
| IPO Year | 2015 | 2017 |
| Metric | NGVT | ZLAB |
|---|---|---|
| Price | $68.94 | $18.54 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 5 |
| Target Price | ★ $72.50 | $49.60 |
| AVG Volume (30 Days) | 219.6K | ★ 634.6K |
| Earning Date | 05-06-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 61.10 | 38.46 |
| EPS | ★ 1.66 | N/A |
| Revenue | ★ $1,167,600,000.00 | $460,156,000.00 |
| Revenue This Year | $3.63 | $9.75 |
| Revenue Next Year | $0.50 | $26.03 |
| P/E Ratio | $41.42 | ★ N/A |
| Revenue Growth | N/A | ★ 15.33 |
| 52 Week Low | $39.74 | $15.96 |
| 52 Week High | $79.29 | $44.34 |
| Indicator | NGVT | ZLAB |
|---|---|---|
| Relative Strength Index (RSI) | 45.38 | 40.39 |
| Support Level | $63.60 | $18.29 |
| Resistance Level | $77.72 | $19.64 |
| Average True Range (ATR) | 2.09 | 0.97 |
| MACD | -0.47 | -0.18 |
| Stochastic Oscillator | 37.53 | 15.45 |
Ingevity Corp is a chemical manufacturer based in the United States. It conducts its operations through three segments, namely Performance Chemicals, Advanced Polymer Technologies, and Performance Materials. The bulk of its revenue is generated by the Performance Chemicals segment which deals with the manufacture and sale of specialty chemicals that find their use in a range of processes such as asphalt paving, oil exploration and production, agrochemicals, adhesives, lubricants, and publication inks. The Performance Materials segment, on the other hand, focuses on automotive carbon products used in automobiles. The Advanced Polymer Technologies segment produces caprolactone and caprolactone-based specialty polymers. The company generates the majority of its revenue from North America.
Zai Lab Ltd is a biopharmaceutical company focusing on discovering or licensing, developing, and commercializing proprietary therapeutics that address areas of unmet medical need including in the fields of oncology, autoimmune and infectious diseases. Zai Lab has a diverse pipeline of potentially first-in-class product candidates developed through in-house R&D and global partnerships. The company has successfully commercialized several products in China, including Zejula, Optune, Qinlock, and Nuzyra, with plans for further expansion The pipeline of proprietary drug candidates of the company includes ZL-1222, ZL-1311, ZL-6201 and many others.